由中间监护病房改建的ICU收治COVID-19 ARDS患者的肺保护性通气依从性与结局
该回顾性观察研究纳入两个学术医疗中心2020年3月至2021年5月收治的成人COVID-19有创机械通气且符合ARDS氧合标准(PaO2/FiO2≤300 mmHg或SpO2/FiO2≤315)的患者,比较在IMCU/ICU与既存内科ICU(MICU)治疗者的肺保护性通气(LPV)依从性和结局。限制性LPV定义为潮气量/预测体重(Vt/PBW)≤6.5 mL/kg且平台压(Pplat)≤30 cmH2O;扩展定义另要求Pplat>30 cmH2O时Vt/PBW<6.0 mL/kg。第一期间限制性定义依从性IMCU/ICU组133例为92%(95%CI 50-100),MICU组199例为100%(86-100),p=0.05;第二期间两组相似(100%[75-100] vs 95%CI[65-100],p=0.68)。全研究期IMCU/ICU组90天死亡校正风险低于MICU组(HR 0.73[95%CI 0.55-0.99]),第28天脱机两组相似(校正亚分布HR 1.09[95%CI 0.85-1.39])。作者认为,在资源、方案和人员配备充足时,IMCU可为急性呼吸衰竭患者提供有效的额外ICU能力。
要点
- 全研究期IMCU/ICU组90天死亡校正风险低于MICU组(HR 0.73[95%CI 0.55-0.99]),第28天脱机两组相似(校正亚分布HR 1.09[95%CI 0.85-1.39])。
- 第一期间限制性LPV依从性IMCU/ICU组133例为92%(95%CI 50-100),MICU组199例为100%(86-100),p=0.05。
- 第二期间限制性LPV依从性两组相似(100%[75-100] vs 95%CI[65-100],p=0.68)。
- 采用扩展LPV定义时观察到相似的模式。
- 作者认为,在资源、方案和人员配备充足时,IMCU可为急性呼吸衰竭患者提供有效的额外ICU能力。
适用人群与场景
- 成人COVID-19患者,接受有创机械通气,且符合ARDS氧合标准(PaO2/FiO2≤300 mmHg或SpO2/FiO2≤315)。
- 研究场景为两个学术医疗中心,2020年3月至2020年9月(第一期间)和2020年10月至2021年5月(第二期间),涵盖该医疗系统前两波COVID-19疫情。
诊断标准与关键阈值
- ARDS氧合标准:PaO2/FiO2≤300 mmHg或SpO2/FiO2≤315。
- 限制性LPV定义:机械通气最初48小时内Vt/PBW≤6.5 mL/kg且Pplat≤30 cmH2O,依从性以符合该定义的时长百分比表示。
- 扩展LPV定义:在限制性定义基础上,若Pplat>30 cmH2O,则Vt/PBW须<6.0 mL/kg。
研究设计与关键结果
- 研究类型:回顾性观察研究,使用电子病历数据;两个学术医疗中心;无干预。
- 第一期间限制性LPV依从性:IMCU/ICU组133例为92%(95%CI 50-100),MICU组199例为100%(86-100),p=0.05。
- 第二期间限制性LPV依从性:IMCU/ICU组100%(75-100)vs MICU组95%CI(65-100),p=0.68。
- 采用扩展LPV定义时观察到相似的模式。
- 全研究期90天死亡校正风险:IMCU/ICU组低于MICU组,HR 0.73(95%CI 0.55-0.99)。
- 第28天脱机:两组相似,校正亚分布HR 1.09(95%CI 0.85-1.39)。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在资源、方案和人员配备充足时,IMCU可为急性呼吸衰竭患者提供有效的额外ICU能力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: During the COVID-19 pandemic, some centers converted intermediate care units (IMCUs) to COVID-19 ICUs (IMCU/ICUs). In this study, we compared adherence to lung protective ventilation (LPV) and outcomes for patients with COVID-19-related acute respiratory distress syndrome (ARDS) treated in an IMCU/ICU versus preexisting medical ICUs (MICUs).
DESIGN: Retrospective observational study using electronic medical record data.
SETTING: Two academic medical centers from March 2020 to September 2020 (period 1) and October 2020 to May 2021 (period 2), which capture the first two COVID-19 surges in this health system.
PATIENTS: Adults with COVID-19 receiving invasive mechanical ventilation who met ARDS oxygenation criteria (Pao2/Fio2 ≤ 300 mm Hg or Spo2/Fio2 ≤ 315).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We defined LPV adherence as the percent of the first 48 hours of mechanical ventilation that met a restrictive definition of LPV of, tidal volume/predicted body weight (Vt/PBW) less than or equal to 6.5 mL/kg and plateau pressure (Pplat) less than or equal to 30 cm H2o. In an expanded definition, we added that if Pplat is greater than 30 cm H2o, Vt/PBW had to be less than 6.0 mL/kg. Using the restricted definition, period 1 adherence was lower among 133 IMCU/ICU versus 199 MICU patients (92% [95% CI, 50-100] vs. 100% [86-100], p = 0.05). Period 2 adherence was similar between groups (100% [75-100] vs. 95% CI [65-100], p = 0.68). A similar pattern was observed using the expanded definition. For the full study period, the adjusted hazard of death at 90 days was lower in IMCU/ICU versus MICU patients (hazard ratio [HR] 0.73 [95% CI, 0.55-0.99]), whereas ventilator liberation by day 28 was similar between groups (adjusted subdistribution HR 1.09 [95% CI, 0.85-1.39]).
CONCLUSIONS: In patients with COVID-19 ARDS treated in an IMCU/ICU, LPV adherence was similar to, and observed survival better than those treated in preexisting MICUs. With adequate resources, protocols, and staffing, IMCUs provide an effective source of additional ICU capacity for patients with acute respiratory failure.
参考来源
- Hochberg CH, Case AS, Psoter KJ, et al. Lung Protective Ventilation Adherence and Outcomes for Patients With COVID-19 Acute Respiratory Distress Syndrome Treated in an Intermediate Care Unit Repurposed to ICU Level of Care. Crit Care Explor. 2024. PMID: 39018303. doi:10.1097/CCE.0000000000001127
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。